Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.
A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.
Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.
The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Greenbrae, California, United States
-
Los Banos, California, United States
-
San Diego, California, United States
-
Walnut Creek, California, United States
-
West Hills, California, United States
-
-
Colorado
-
Lakewood, Colorado, United States
-
Longmont, Colorado, United States
-
-
Florida
-
Boynton Beach, Florida, United States
-
Hialeah, Florida, United States
-
Jupiter, Florida, United States
-
-
Georgia
-
Dunwoody,, Georgia, United States
-
Gainesville, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Idaho
-
Idaho Falls, Idaho, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Iowa
-
Des Moines, Iowa, United States
-
Iowa City, Iowa, United States
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Metarie, Louisiana, United States
-
-
Maine
-
Scarborough, Maine, United States
-
-
Maryland
-
Bethesda, Maryland, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
Mineola, New York, United States
-
West Haverstraw, New York, United States
-
-
North Carolina
-
Pinehurst, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
South Carolina
-
Aiken, South Carolina, United States
-
Greenville, South Carolina, United States
-
-
Tennessee
-
Brentwood, Tennessee, United States
-
-
Texas
-
Denton, Texas, United States
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is female and has not experienced menses for at least 5 years.
- Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.
- Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).
- Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods.
- Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor.
- Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening.
Exclusion Criteria:
- Has a fasting triglyceride level greater than 500 mg/dL.
- Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays.
- Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice.
- Has Vitamin D (25-OH-D) less than 20 ng/mL.
- Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.
- Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.
Has any of the following disorders:
- Rheumatoid Arthritis
- Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism.
- A personal history of kidney stones.
- Has a clinical history after age 45 of wrist, hip, or leg fractures.
- Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.
- Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.
- Has signs and/or symptoms of heart failure.
- Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.
- Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.
- Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
- Has a history of breast cancer.
- Is taking or has ever taken pioglitazone or other Thiazolidinediones.
- Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Other Names:
|
|
Experimental: Pioglitazone
|
Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)
Time Frame: Baseline and Month 12.
|
The change in bone mineral density in the total proximal femur at month 12 relative to baseline.
DXA is a means of measuring BMD through x-ray.
|
Baseline and Month 12.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA
Time Frame: Month 12 and Month 18.
|
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.
|
Month 12 and Month 18.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Fasting Plasma Glucose (FPG)
Time Frame: Baseline and Month 12; Month 12 and Month 18.
|
The change between the fasting plasma glucose value collected at each time frame indicated.
|
Baseline and Month 12; Month 12 and Month 18.
|
|
Number of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)
Time Frame: Up to 18 months.
|
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL.
Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up).
Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug.
Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.
|
Up to 18 months.
|
|
Number of Participants With Fracture
Time Frame: Up to 18 months.
|
Number of participants with confirmed (through an adjudication process) fractures during the study.
Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.
|
Up to 18 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Ipsen EO, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.
- Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AD-4833_402
- U1111-1115-0660 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.